GLP-1 medications work by turning down appetite. For most people, that's the whole point. But if you have a history of an eating disorder — or you're living with one now — "eats less, thinks about food less, loses weight quickly" is not a neutral description. It reads like a list of the exact features you may have worked hard to recover from. So it's reasonable to ask a hard question before you start: is this safe for someone like me? The honest answer is that the evidence is early, genuinely mixed, and points less to a simple yes-or-no than to who needs to be involved in the decision with you.
The genuine concerns
The worry isn't imaginary. GLP-1 medications reduce hunger and increase fullness — for someone with a history of restriction (as in anorexia nervosa or restrictive disordered eating), a medication that makes eating less feel effortless can quietly reinforce the very patterns recovery was meant to interrupt. What looks like a "good response" to the drug — smaller portions, less interest in food, dropping weight — can be hard to tell apart from a relapse dressed in medical clothing.
Rapid weight loss brings its own risk. Losing weight fast can intensify preoccupation with the body, and changes some people notice on a GLP-1 — loose skin, facial thinning — can stir up distress, especially if body image has been a struggle before. If you're not sure whether what you're feeling is normal adjustment or something more, our guide on body-image lag versus body dysmorphia walks through the difference. A history of disordered eating raises the odds that fast change lands hard rather than neutrally.
What the emerging research actually shows
The picture is not all caution, and it's important not to overstate the harm either. Interestingly, the research signal that does exist is mostly on the opposite end of the eating-disorder spectrum: binge eating disorder (BED), the most common eating disorder, which involves recurrent loss-of-control eating rather than restriction.
Based on articles retrieved from PubMed, a 2026 systematic review and meta-analysis found that liraglutide (a GLP-1 medication) reduced binge frequency in binge eating disorder compared with placebo — while stressing that the certainty of evidence was low and the findings are hypothesis-generating, not a green light (Choudhury et al., , 2026, ). Two other systematic reviews echo this: early findings suggest GLP-1 medications may reduce binge-eating behavior, but the authors are explicit that large, blinded, placebo-controlled trials are still lacking, so this should not yet be treated as established therapy (Aoun et al., , 2024, ; Carminati et al., , 2025, ).